This product has not been evaluated by Health Canada
That means we listen closely to your goals, your challenges, and your lifestyle, and we recommend only what's medically responsible and truly beneficial for you
September 20 Product: Zevra Therapeutics Miplyffa Indication: Niemann-Pick disease type C Patients with Niemann-Pick disease type C (NPC) have their first treatment after the FDA approved Zevra Therapeutics Miplyffa for the ultra-rare, progressive neurodegenerative disease
The mechanism behind this is synergistic rather than additive
HIF-1, as a pivotal regulator response to oxygen homeostasis, metabolism, inflammation and in crosstalk with mitochondria, is the underlying mechanism of determining disease progression in PH [36,37,38,39]